Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7345608 | 0.81 | KDM4E (0.61) | AGXTKDM4EMAPK1TDP1PTPN7 | |
| SCHEMBL9043883 | 0.80 | CA12 (0.57) | AGXTKDM4EMAPK1TDP1PTPN7 | |
| SCHEMBL11026671 | 0.80 | AGXT (0.57) | AGXTKDM4EMAPK1TDP1PTPN7 | |
| SCHEMBL7860885 | 0.79 | ALDH1A1 (0.51) | KDM4EMAPK1MEN1KMT2AHTT | |
| SCHEMBL2170360 | 0.78 | CA12 (0.42) | KDM4ETDP1MEN1KMT2ANPSR1 | |
| SCHEMBL7960647 | 0.77 | AGXT (0.53) | AGXTKDM4EMAPK1TDP1PTPN7 | |
| SCHEMBL3624437 | 0.77 | AGXT (0.63) | AGXTKDM4EMAPK1TDP1PTPN7 | |
| SCHEMBL7347275 | 0.77 | HDAC1 (0.56) | AGXTKDM4EMAPK1TDP1PTPN7 | |
| SCHEMBL16902860 | 0.76 | AGXT (0.68) | AGXTKDM4EMAPK1TDP1PTPN7 | |
| SCHEMBL24458 | 0.76 | KCNA3 (0.50) | LMNAALDH1A1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3657002-B2 | — | — | 2005-06-08 | — | — | JP | claimed |
| WO-2004065411-A2 | PEPTIDES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-08-05 | — | — | WO | claimed |
| US-6762187-B2 | HETEROCYCLIC NITROGEN COMPOUNDS USED AS ENZYME INHIBITORS FOR PROPHYLAXIS OF HUMAN IMMUNODEFICIENCY VIRUS(HIV) | MONSANTO COMPANY | 2004-07-13 | — | — | US | claimed |
| US-20030195227-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 2003-10-16 | — | — | US | claimed |
| US-6506759-B1 | Method for treating HIV-related AIDS comprising administering an effective amount of a composition N-heterocyclic moiety containing hydroxyethylamine compounds are effective as retroviral protease inhibitors, and in | MONSANTO COMPANY | 2003-01-14 | — | — | US | claimed |
| US-6388081-B1 | 4-substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries | LION BIOSCIENCE AG (DE) | 2002-05-14 | — | — | US | claimed |
| EP-1148050-A1 | Retroviral protease inhibitors | MONSANTO COMPANY (US) | 2001-10-24 | — | — | EP | claimed |
| EP-1119357-A1 | C3A RECEPTOR LIGANDS | SmithKline Beecham Corporation (US) | 2001-08-01 | — | — | EP | claimed |
| US-6262269-B1 | 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries | TREGA BIOSCIENCES, INC. | 2001-07-17 | — | — | US | claimed |
| EP-0641325-B1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO CO (US) | 2001-03-07 | — | — | EP | claimed |
| EP-0410989-A4 | CYCLIC ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | — | 1991-06-05 | — | — | EP | claimed |
| EP-0410989-A1 | CYCLIC ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY, INC. (US) | 1991-02-06 | — | — | EP | claimed |
| US-4935492-A | Cyclic analogs of atrial natriuretic peptides | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1990-06-19 | — | — | US | claimed |
| WO-1989009611-A1 | CYCLIC ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1989-10-19 | — | — | WO | claimed |
| EP-0323740-A2 | Linear analogs of atrial natriuretic peptides | CALIFORNIA BIOTECHNOLOGY, INC. (US) | 1989-07-12 | — | — | EP | claimed |
| WO-1989005654-A1 | LINEAR ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1989-06-29 | — | — | WO | claimed |
| EP-0315367-A2 | Polypeptides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-10 | — | — | EP | claimed |
| US-4804650-A | DIURETICS, VASODILATORS | BIOTECHNOLOGY RESEARCH ASSOCIATES, J.V. (US) | 1989-02-14 | — | — | US | claimed |
| EP-0223143-A2 | Analogs of atrial natriuretic peptides | CALIFORNIA BIOTECHNOLOGY, INC. (US) | 1987-05-27 | — | — | EP | claimed |
| WO-1987002674-A1 | ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | BIOTECHNOLOGY RESEARCH ASSOCIATES, J.V. (US) | 1987-05-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195227-A1 | Retroviral protease inhibitors | MME, PREP, TMPRSS15 | AGXT 1299/4885KDM4E 940/4885MAPK1 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.